Innovent Biologics
Innovent Biologics, also known as Innovent, is a leading biopharmaceutical company headquartered in Suzhou, China, with significant operations across Asia and beyond. Founded in 2011, Innovent has rapidly established itself in the biotechnology industry, focusing on the development, manufacturing, and commercialisation of innovative therapies for oncology, autoimmune diseases, and other serious conditions. The company is renowned for its core products, including monoclonal antibodies and biosimilars, which are distinguished by their high quality and efficacy. Innovent's commitment to research and development has led to several key milestones, including successful partnerships and a robust pipeline of drug candidates. With a strong market position, Innovent Biologics continues to make notable strides in improving patient outcomes and advancing healthcare solutions globally.
DitchCarbon Score
How does Innovent Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Development industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innovent Biologics's score of 27 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Innovent Biologics's reported carbon emissions
In 2023, Innovent Biologics reported total carbon emissions of approximately 15.9 million tonnes CO2e. This figure includes 65,170 tonnes CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and about 15.8 million tonnes CO2e from Scope 2 emissions, which are indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Notably, there were no reported Scope 3 emissions in 2023. In previous years, the company recorded emissions of approximately 22.3 million tonnes CO2e in 2022, 16 million tonnes CO2e in 2021, and 39,400 tonnes CO2e in 2019, indicating a significant fluctuation in emissions over the years. The increase in emissions from 2019 to 2021 can be attributed to growth in operations and revenue, which reached about USD 899.7 million in 2023. Despite these figures, Innovent Biologics has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company’s emissions data reflects its operational scale and highlights the importance of ongoing monitoring and potential future commitments to reduce its carbon footprint in alignment with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2019 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 39,400 | - | - | 00,000 |
| Scope 2 | 39,400 | 00,000 | 00,000 | 00,000,000 |
| Scope 3 | - | 0,000,000 | 0,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Innovent Biologics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
